Clinical trials
Metastatic Skin Squamous Cell Carcinoma clinical trials
Below are recruiting metastatic skin squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 285 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04883671Recruiting
SBRT to treat a few spots of adenoid cystic cancer
This trial tests whether focused radiation (SBRT) can help control adenoid cystic carcinoma that has spread to a small number of places (oligometastatic disease). If you qualify, the study will treat up to 1–5 metastatic spots that doctors think can be safely targeted, to help control the cancer locally.
San Francisco, CaliforniaAges 18 years+ - NCT07070479RecruitingPhase 2
Combination treatment for PD-1 resistant nasopharyngeal cancer
This trial is testing a combination of drugs for people whose nasopharyngeal cancer has stopped responding to standard treatments like platinum chemotherapy and PD-1 inhibitors. It aims to find a new effective approach for advanced or recurrent disease.
Guangzhou, GuangdongAges 18–70 - NCT04305834RecruitingPhase 2
Abemaciclib plus hormone pills for metastatic breast cancer in older adults
This Phase 2 study tests whether abemaciclib combined with standard hormone (endocrine) therapy can better control metastatic breast cancer in people age 70 and older. It may help if your cancer has already grown despite prior hormone therapy and/or other cancer medicines.
Duarte, CaliforniaAges 70 years+ - NCT07625644RecruitingPhase 3
New immunotherapy combination for advanced lung cancer
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
Springdale, ArkansasAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Anchorage, AlaskaAges 18 years+ - NCT06512051RecruitingPhase 1/Phase 2
Study of SHR-A2102 and Adebrelimab for advanced lung cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–70 - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT03467360RecruitingPhase 1
Adding an acetazolamide-type drug to lung cancer radiation and drugs
This Phase 1 trial tests whether blocking an enzyme (with an acetazolamide-like medicine) can be safely combined with standard treatment for small cell lung cancer that has not spread. The goal is to see if the treatment can be given safely and to learn early signs of benefit.
NiceAges 18 years+ - NCT07770802RecruitingPhase 1
Study of an investigational cell therapy for advanced kidney cancer
This trial tests an investigational medicine called HS-IT101 for people with advanced kidney cancer that hasn't responded to standard treatments. The goal is to see if this new therapy can help shrink or control the cancer.
BeijingAges 18–75 - NCT06690697RecruitingPhase 2
Toripalimab and JS004 for advanced kidney cancer
This trial tests a combination of two drugs, toripalimab and JS004, for patients with advanced kidney cancer that has returned or spread. It aims to see if this therapy can help when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07135882RecruitingPhase 3
Radiotherapy for lung cancer that has spread
This trial tests whether giving radiotherapy to the main lung tumor, along with the usual medicines (like chemotherapy or immunotherapy), can help people with stage IV lung cancer. The goal is to see if adding this treatment helps control the cancer and improves how long patients live.
Gold Coast, QueenslandAges 18 years+ - NCT07581821RecruitingPhase 2
Immunotherapy plus targeted drugs for advanced nasopharyngeal cancer
This trial tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) for nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this combination helps slow or shrink the cancer.
Zhuhai, GuangdongAges 18–65 - NCT07258979RecruitingPhase 1/Phase 2
YL201 and Toripalimab with or without Cisplatin for Nasopharyngeal Cancer
This trial tests a new drug combination for people with advanced or recurrent nasopharyngeal cancer. It aims to see if YL201 plus Toripalimab (and sometimes cisplatin) can help when standard treatments are not an option.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05422794RecruitingPhase 1
Adding a new drug plus pembrolizumab to standard chemo for TNBC
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
Boston, MassachusettsAges 18 years+ - NCT05994170Recruiting
Lower radiation dose to tumor area for early nasopharyngeal cancer
This trial studies whether lowering the radiation dose to a smaller area around the tumor is safe and effective for people with newly diagnosed nasopharyngeal cancer that has not spread. It may reduce side effects while still curing the cancer.
Zhongshan, GuangdongAges 18–70 - NCT06805617RecruitingPhase 2
Ivonescimab for advanced salivary gland cancer
This trial tests a new drug called Ivonescimab for people with advanced salivary gland cancer that has spread or cannot be removed surgically. The goal is to see if the drug can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT07419841RecruitingPhase 1
A study of CTX-10726 for certain advanced cancers
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Phoenix, ArizonaAges 18 years+ - NCT06689540RecruitingPhase 1
MTS105 for advanced liver cancer with GPC3
This trial tests a new treatment called MTS105 for people with advanced liver cancer (HCC) that has not responded to standard therapies. It targets a protein called GPC3 found on some liver cancer cells, aiming to stop the cancer from growing.
BeijingAges 18 years+ - NCT05799144RecruitingPhase 2
Pembrolizumab plus investigational HPV drugs for throat cancer
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Birmingham, AlabamaAges 18 years+ - NCT07647744RecruitingPhase 1
CD70-Targeted Cell Therapy for Advanced Kidney Cancer
This study tests a new cell-based treatment designed to target kidney cancer cells that have a protein called CD70. The treatment involves collecting your immune cells, modifying them in the lab, and infusing them back to fight the cancer. It's for patients with advanced kidney cancer who have already tried at least one standard immunotherapy.
ShanghaiAges 18–70 - NCT06472713RecruitingPhase 2
Liposomal mitoxantrone with immunotherapy for advanced nasopharyngeal cancer
This trial tests a combination of a chemotherapy drug (mitoxantrone liposome) with an immunotherapy (PD-1 blocker) for people whose nasopharyngeal cancer has come back or spread and hasn't responded to previous treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Zhuhai, GuangdongAges 18–70 - NCT07422779Recruiting
Immunotherapy for advanced melanoma study
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
LjubljanaAges 18 years+ - NCT07213557RecruitingPhase 2
Simvastatin with immunotherapy for ARID1A-mutated stomach cancer
This trial tests whether adding the cholesterol drug simvastatin to standard immunotherapy and chemotherapy can help people with a specific type of gastroesophageal cancer (ARID1A mutated, HER2 negative). It is for patients who have not had prior treatment for advanced disease.
Naples, ItaliaAges 18 years+ - NCT06587802RecruitingPhase 2
PD-1 antibody and radiation for advanced adrenal cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
Guangzhou, GuangdongAges 18 years+
Hear when a new Metastatic Skin Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic skin squamous cell carcinoma?
- Yes. Clin2 currently lists 285 recruiting metastatic skin squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic skin squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic skin squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Clear Cell Renal Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Skin
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Oropharyngeal Squamous Cell Carcinoma
- Metastatic Hypopharyngeal Squamous Cell Carcinoma
- Metastatic Laryngeal Squamous Cell Carcinoma
- Metastatic Oral Cavity Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.